“Despite increased cancer survivorship overall, there continues to be a significant unmet need in oncology,” said Marianne De Backer, MBA, PhD, Member of the Executive Committee of the Pharmaceuticals Division and Head Strategy and Business Development & Licensing at Bayer. “We remain committed to exploring collaborations for innovative and pioneering scientific research for patients with unmet needs.”
Financial terms of the agreement were not disclosed.
Ad Statistics
Times Displayed: 364920
Times Visited: 6942 Quality remanufactured Certified Centrifuges at Great prices! Fully warranted and backed by a company you can trust! Call or click for a free quote today! www.Centrifugestore.com 800-457-7576
About Targeted Alpha Therapies (TAT) at Bayer
Targeted Alpha Therapies (TAT) are a class of radionuclide compounds being studied in various difficult to treat tumors. They deliver alpha radiation to tumors inside the body either via their bone-seeking property (radium-223) or by combining alpha radionuclides, such as, actinium-225 or thorium-227, with specific moieties.
Bayer’s Xofigo® (radium Ra 223 dichloride) is the first and only approved TAT. Xofigo is indicated for the treatment of patients with mCRPC, symptomatic bone metastases and no known visceral metastatic disease. More than 76,000 patients have been treated worldwide since launch. Xofigo is currently under further evaluation in a broad clinical development program.
With its proprietary platform of investigational targeted thorium conjugates (TTC), Bayer is advancing a series of drug candidates with potential across multiple cancers. PSMA-TTC, which is combining a prostate-specific membrane antigen (PSMA)-targeting antibody with thorium-227, is a leading TTC project at Bayer. It is currently in Phase I clinical evaluation in patients with metastatic castration-resistant prostate cancer. PSMA is highly expressed on the surface of prostate cancer cells. With this acquisition, Bayer broadens its existing TAT development portfolio by adding an actinium-labeled PSMA-targeted alpha therapy. It is planned to be investigated as a treatment option across multiple stages of prostate cancer.
About Prostate Cancer at Bayer
Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The company has the passion and determination to develop new medicines for people living with cancer. Prostate cancer is the second most commonly diagnosed cancer in men1 and a key area of focus for Bayer. The company’s franchise includes two products on the market (Nubeqa® and Xofigo®) and several compounds in development, including advancing targeted alpha therapies. Bayer is focused on addressing the medical needs of prostate cancer patients.
